Transactions November 12, 2026

Vimy Pharmaceuticals Corp. Completes Go-Public Transaction

Vimy Pharmaceuticals Corp. (TSXV: VIMY), formerly Harmony Acquisitions Corp., completed its business combination with Vimy Pharmaceuticals Inc. by way of a three-cornered amalgamation, constituting Vimy Pharma’s “go public” transaction. The common shares of the resulting issuer are expected to commence trading on the TSX Venture Exchange under the ticker symbol VIMY on or about November 17, 2026.

 

In connection with the transaction, Vimy Pharmaceuticals Inc. completed an upsized brokered private placement in two tranches for aggregate gross proceeds of over $14.5 million. The financing was led by Beacon Securities Limited, on behalf of a syndicate of agents that included Haywood Securities Inc., Leede Financial Inc. and Research Capital Corporation.

 

Vimy Pharma is a Canadian pharmaceutical company focused on improving access to affordable medicines while supporting domestic pharmaceutical manufacturing capacity and long-term Canadian supply resilience. Vimy Pharma is advancing a portfolio of essential medicines as generic pharmaceutical products intended to support patients, healthcare systems, and Canada’s life sciences sector. Earlier this year, Vimy Pharma completed one of its development programs and filed an Abbreviated New Drug Submission (ANDS) with Health Canada, which has been found acceptable for review, for a generic version of Ozempic® (semaglutide injection), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes. Vimy Pharma has also filed an ANDS with Health Canada for a generic version of Wegovy® (semaglutide injection), a GLP-1 receptor agonist indicated for weight management. Vimy Pharma undertook its development work in Canada and will carry out its commercial production domestically, with Canadian partners.

 

Wildeboer Dellelce LLP acted for Vimy Pharma in connection with the qualifying transaction and concurrent financing with a team comprised of Michael Rennie, Natalie Tershakowec, Alex Karlsen, Jason Kim and Isabelle Logan (corporate finance & securities; life sciences, healthcare & pharmaceuticals), together with Jesse Brodlieb (tax).

Wildeboer Dellelce LLP